Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab

Hepatitis B virus (HBV) reactivation in the setting of rituximab use is a potentially fatal but preventable safety event. The rate of HBV screening and proportion of patients at risk who receive antiviral prophylaxis in patients initiating rituximab is unknown. We analyzed electronic health record (...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Medicine (Baltimore)
Egile Nagusiak: Schmajuk, Gabriela, Tonner, Chris, Trupin, Laura, Li, Jing, Sarkar, Urmimala, Ludwig, Dana, Shiboski, Stephen, Sirota, Marina, Dudley, R. Adams, Murray, Sara, Yazdany, Jinoos
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2017
Gaiak:
5400
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380298/
https://ncbi.nlm.nih.gov/pubmed/28353614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000006528
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak